Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Purchased by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Ovid Therapeutics Inc. (NASDAQ:OVID) by 50.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 943,416 shares of the company’s stock after purchasing an additional 315,126 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Ovid Therapeutics were worth $881,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. SG Americas Securities LLC boosted its holdings in shares of Ovid Therapeutics by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock valued at $35,000 after buying an additional 17,172 shares during the period. Bank of America Corp DE raised its stake in Ovid Therapeutics by 49.7% during the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after acquiring an additional 18,841 shares during the period. Rhumbline Advisers lifted its holdings in Ovid Therapeutics by 22.3% in the fourth quarter. Rhumbline Advisers now owns 84,078 shares of the company’s stock worth $79,000 after acquiring an additional 15,355 shares during the last quarter. Barclays PLC boosted its stake in Ovid Therapeutics by 311.2% in the third quarter. Barclays PLC now owns 84,175 shares of the company’s stock valued at $98,000 after acquiring an additional 63,702 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Ovid Therapeutics by 142.0% in the fourth quarter. Renaissance Technologies LLC now owns 107,700 shares of the company’s stock valued at $101,000 after acquiring an additional 63,200 shares during the period. 72.24% of the stock is owned by institutional investors and hedge funds.

Ovid Therapeutics Stock Performance

Shares of NASDAQ OVID opened at $0.29 on Wednesday. Ovid Therapeutics Inc. has a 12-month low of $0.24 and a 12-month high of $3.43. The company has a market cap of $20.34 million, a PE ratio of -0.61 and a beta of 0.27. The stock has a 50 day simple moving average of $0.35 and a 200-day simple moving average of $0.71. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.18.

Ovid Therapeutics (NASDAQ:OVID) last announced its earnings results on Tuesday, March 11th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.19 million. On average, equities research analysts forecast that Ovid Therapeutics Inc. will post -0.4 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Oppenheimer upgraded Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a research report on Wednesday, January 29th. Wedbush restated an “outperform” rating and set a $3.00 price objective (down from $4.00) on shares of Ovid Therapeutics in a research note on Wednesday, March 12th. BTIG Research cut their target price on Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Monday, March 24th. Finally, William Blair raised shares of Ovid Therapeutics to a “strong-buy” rating in a report on Thursday, April 24th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Ovid Therapeutics presently has a consensus rating of “Buy” and an average price target of $3.03.

Ovid Therapeutics Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.